MTA-Cooperative PRMT5 Inhibitor

Orally bioavailable

An orally bioavailable MTA-cooperative PRMT5 inhibitor with high selectivity and robust antitumor activity in MTAP-deleted tumors.

Ding, Xiao · Aliper, Alexander M. · Ren, Feng · Zhavoronkov, Alex A.

Journal of Medicinal Chemistry 2025

Advantages

Strong antiproliferation activity in multiple MTAP-deleted cancer cell lines

Excellent selectivity over MTAP wild-type cell lines

Satisfactory oral pharmacokinetic properties in various preclinical species

Dose-dependent SDMA reduction and robust in vivo antitumor activity in LU99 subcutaneous model